Merck & Co has announced today in a press release, before Wall Street opened, positive results from the Phase-III Keynote-042 clinical trial, conducted on 1,274 patients with metastatic, squamous and non squamous, non-small cell lung cancer, treated with immunotherapy Keytruda (PD-L1 inhibitor). The results show that Keytruda has reached the primary endpoint of overall survival vs conventional chemotherapy. These positive results have encouraged Merck & Co to continue the clinical trial, with the aim to reach the secondary endpoints, which include progression-free survival (PFS). Merck & Co. currently has over 700 clinical trials ongoing with Keytruda. The company’s shares have soon reacted to the good news by rising more than 3% as trading started.
(Source Merck & Co.)